How does erlotinib inhibit EGFR?
Erlotinib (Tarceva) belongs to a class of drugs known as tyrosine kinase inhibitors. It works by blocking the function of a protein called the epidermal growth factor receptor (EGFR). The EGFR is found on the surface of many cancer cells as well as normal cells.
What is the treatment after Tagrisso?
In this trial some of these patients responded to a combination of the immunotherapy Tecentriq (atezolizumab), chemotherapy, and a drug called Avastin (bevacizumab). Since IMpower150, some doctors may recommend an immunotherapy combination treatment for certain patients that have progression after receiving Tagrisso.
How do you treat GFR?
To treat EGFR-positive squamous cell lung cancer, healthcare providers use a combination of chemotherapy and immunotherapy. And there are a growing number of therapies for patients with tumors who have specific types of genetic mutations, like exon abnormalities.
How long is Tarceva effective?
The overall anti-cancer response rate was 9% for patients treated with Tarceva™ and the average duration of response was nearly 8 months. Disease stabilization was achieved in 35% of patients treated with Tarceva™ and progression of cancer occurred in 38% of patients treated with Tarceva™.
What class drug is erlotinib?
Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
How long does TAGRISSO extend life?
People taking TAGRISSO lived significantly longer than people taking erlotinib or gefitinib. The median overall survival was 38.6 months for TAGRISSO vs 31.8 months for erlotinib or gefitinib.
How long will TAGRISSO work?
Tagrisso showed a 52% reduction in risk of central nervous system disease progression or death
| Tagrisso (n=279) | |
|---|---|
| Survival at 12 months (95% CI) | 89.1% (84.8-92.2) |
| Survival at 24 months (95% CI) | 74.2% (68.6-79.0) |
| Survival at 36 months (95% CI) | 53.7% (47.5-59.5) |
| CNS PFS (secondary endpoint)i,1 |
What type of drugs are EGFR inhibitors?
EGFR inhibitors used in NSCLC with EGFR gene mutations
- Erlotinib (Tarceva)
- Afatinib (Gilotrif)
- Gefitinib (Iressa)
- Osimertinib (Tagrisso)
- Dacomitinib (Vizimpro)